Sign In
Buy HCWB
$1.68
-0.110 (-6.15%)
At Close: Jun 03, 2026
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
07:45am, Wednesday, 27'th May 2026
Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market Recently published data suggest that HCW9206 may reduce CAR-T production costs and improve therape
E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement
04:02pm, Friday, 22'nd May 2026
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
09:53am, Thursday, 21'st May 2026
MIRAMAR, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusi
HCW Biologics (HCWB) Stock Is Trending Overnight — Here's Why It Moved Over 122% In After-Hours Session
11:21pm, Thursday, 14'th May 2026
HCW Biologics Inc. surged 122.55% in after-hours trading after reporting first-quarter EPS that sharply exceeded analyst expectations.
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
04:25pm, Thursday, 14'th May 2026
MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transform
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies
07:30am, Thursday, 14'th May 2026
HCW11-040 is a pembrolizumab-based fusion immunotherapeutic that activates immune cells and eliminates high-oxygen induced senescent cells
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
04:20pm, Thursday, 30'th Apr 2026
MIRAMAR, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fu
Its lead T-Cell Engager HCW11-018b is shown to penetrate into the tumor microenvironment with potent and antigen-specific anti-pancreatic cancer activities
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results
05:05pm, Tuesday, 31'st Mar 2026
MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fus
HCW Biologics (HCWB) Projected to Post Earnings on Wednesday
02:48am, Wednesday, 25'th Mar 2026
HCW Biologics (NASDAQ: HCWB - Get Free Report) is expected to be announcing its results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.84) per
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
07:50am, Tuesday, 17'th Mar 2026
Upfront cash fee with total value of $7.0 million, comprised of a $3.5 million cash payment and $3.5 million in-kind payment in the form of a transferable equity interest in licensee
Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer
HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter
08:00am, Monday, 02'nd Mar 2026
MIRAMAR, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on discovering and de
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
09:50pm, Tuesday, 17'th Feb 2026
MIRAMAR, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing inn
HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune
08:30am, Friday, 13'th Feb 2026
HCW Biologics receiving cash fee and co-founder shares in Trimmunevalued at $7.0 million Trimmune will hold exclusive worldwide license for rights to high potential preclinical molecule created with H
